SEARCH

SEARCH BY CITATION

References

  • 1
    Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy group (IHIT). Lancet 1998; 352: 142632.
  • 2
    McHutchison J, Blatt L, Sedghi-Vaziri A, Russell J, Schmid P, Conrad A. Is there an optimal time to measure quantitative HCV RNA to predict non-response following interferon treatment for chronic HCV infection? Hepatology 1998; 29: 3628.
  • 3
    McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1998; 339: 148592.
  • 4
    Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo controlled trial of interferon alfa-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351: 837.
  • 5
    Schalm SW, Hansen BE, Chemello L et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J. Hepatol. 1997; 26: 9616.
  • 6
    Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999; 30: 131824.
  • 7
    Bennett WG, Inoue Y, Beck JR et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann. Intern. Med. 1997; 127: 85565.
  • 8
    Wong JB, Poynard T, Ling M-H, Albrecht JK, Pauker SG. Cost-effectiveness of 24 or 48 weeks of interferon a-2b alone or with ribavirin as initial treatment of chronic hepatitis C. Am. J. Gastroenterol. 2000; 95: 152430.
  • 9
    McHutchison JG, Ware JE Jr, Bayliss MS et al. The effects of interferon-alpha 2b in combination with ribaravin on health related quality of life and work productivity. J. Hepatol. 2001; 34: 1407.
  • 10
    Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 1998; 28: 11217.
  • 11
    Marcellin P, Boyer N, Gervais A et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann. Intern. Med. 1997; 127: 87581.
  • 12
    Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999; 29: 26470.
  • 13
    Bennett WG, Pauker SG, Davis GL, Wong JB. Modeling therapeutic benefit in the midst of uncertainty: therapy for hepatitis C. Dig. Dis. Sci. 1996; 41: 56S62S.
  • 14
    Perrillo RP. The role of liver biopsy in hepatitis C. Hepatology 1997; 26: 57S61S.
  • 15
    Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C. Risks, Benefits, Costs. JAMA 1998; 280: 208893.
  • 16
    Pawlotsky JM. Measuring hepatitis C viremia in clinical samples: can we trust the assays? Hepatology 1997; 26: 14.
  • 17
    Pawlotsky JM, Bouvier-Alilas M, Hezode C, Darthuy F, Remire J, Dhumeauz D. Standardization of hepatitis C virus RNA quantification. Hepatology 2000; 32: 6549.
  • 18
    Tong MJ, Blatt LM, McHutchison JG, Co RL, Conrad A. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26: 16405.
  • 19
    Blatt LM, Tong MJ, McHutchison JG, Russell J, Schmid P, Conrad A. Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers. J. Interferon Cytokine Res. 1998; 18: 7580.
  • 20
    McHutchison JG, Hoofnagle JH. Therapy of chronic hepatitis C. In: TJ Liang, JH Hoofnagle, eds. Hepatitis C, Biomedical Research Reports. New York: Academic Press, 2001; 20340.
  • 21
    Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The consensus Interferon Study Group. Hepatology 1999; 29: 26470.
  • 22
    Brillanti S, Foli M, Di Tomaso M, Grammantieri L, Masci. C, Bolondi L. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders. Ital. J. Gastroenterol. 1999; 31: 1304.
  • 23
    Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271: 15826.
  • 24
    Carithers RL, Zeuzem S, Manns MP et al. Multicenter, randomized, controlled trial comparing high dose daily induction interferon plus ribavirin versus standard interferon alfa-2B plus ribavirin. Hepatology 2000; 32: 317A.
  • 25
    Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment -naíve patients. Sem. Liver Dis. 1999; 19: 6775.
  • 26
    McHutchison JG, Poynard T, Harvey J, Garaud J-J, Albrecht JK. The Effect of Dose Reduction on Sustained Response in Patients with Chronic Hepatitis C Receiving Interferon alfa-2b in Combination with Ribavirin. AASLD, Dallas, TX. Hepatology 2000; 32: 223A.
  • 27
    Mathurin P, Moussalli J, Cadranel JF et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminases activity. Hepatology 1998; 27: 86872.
  • 28
    Alter HJ, Conry-Cantilena C, Melpolder J et al. Hepatitis C in asymptomatic blood donors. Hepatology 1997; 26: 29S33S.
  • 29
    Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 26: 15S20S.
  • 30
    Persico M, Persico E, Suozzo R et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000; 118: 7604.
  • 31
    Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, Brunt EM, Bacon BR. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon. Hepatology 2001; 33: 7047.
  • 32
    Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 10548.
  • 33
    Darby SC, Ewart DW, Giangrande PL et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Director’s Organisation. Lancet 1997; 350: 142531.
  • 34
    Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin. Infect. Dis. 2001; 32: 4927.
  • 35
    Schalm SW, Weiland O, Hansen BE et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. Gastroenterology 1999; 117: 40813.
  • 36
    Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an ‘a la carte’ combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 2000; 31: 21118.
  • 37
    Poynard T, McHutchison J, Davis GL et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32: 11317.
  • 38
    Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N. Engl. J. Med. 2000; 343: 166672.
  • 39
    Heathcote EJ, Shiffman ML, Cooksley GE et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 2000; 343: 167380.
  • 40
    Lindsay KL, Trepo C, Heintges T. The hepatitis Interventional Therapy Group. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395403.DOI: 10.1053/jhep.2001.26371
  • 41
    Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised controlled trial. Lancet 2001; 358: 95865.
  • 42
    Fried MW, Shiffman ML, Reddy RK et al. Pegylated (40kDa) interferon alfa-2a in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study. (Abstract). Gastroenterology 2001; 120: A55.
  • 43
    Davis GL, Esteban-Mur R, Rustgi V et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1998; 339: 14939.
  • 44
    DiMarco V, Almasio P, Vaccaro A et al. Combined treatment of relapse of chronic hepatitis C with high dose a2b interferon and plus ribavirin for 6 or 12 months. J. Hepatol. 2000; 33: 45662.
  • 45
    Shiffman ML, Hofmann CM, Thompson EB et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997; 26: 7805.